Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irbesartan

FDA-approved product (tablet, oral), marketed as Avapro, Irbesartan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Irbesartan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Chronic renal failure syndrome
  • Diabetic nephropathy
  • Hypertension
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
FDA pharmacologic class
Angiotensin 2 Receptor Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irbesartan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irbesartan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effects of Bindarit in Diabetic Nephropathy

    NCT01109212 · start 2007-03

    Registered record
    Registry ID
    NCT01109212
    Conditions
    Diabetic Nephropathy
    Interventions
    Bindarit; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy
    InterventionBindarit; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

    NCT00265642 · start 2006-10

    Registered record
    Registry ID
    NCT00265642
    Conditions
    Hepatitis C, Chronic
    Interventions
    Irbesartan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-10
    Completion
    2013-11
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionIrbesartan; placebo
    PhasePhase 3
    Registry statusCompleted

  • I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

    NCT00362037 · start 2006-03

    Registered record
    Registry ID
    NCT00362037
    Conditions
    Hypertension
    Interventions
    Irbesartan (Aprovel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-06
    Enrolment
    281

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan (Aprovel)
    PhasePhase 4
    Registry statusCompleted

  • ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation

    NCT00296218 · start 2006-02

    Registered record
    Registry ID
    NCT00296218
    Conditions
    Myocardial Ischemia; Hypertension
    Interventions
    Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-02
    Completion
    Not recorded
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Ischemia; Hypertension
    InterventionIrbesartan
    PhasePhase 3
    Registry statusCompleted

  • I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

    NCT00335673 · start 2006-02

    Registered record
    Registry ID
    NCT00335673
    Conditions
    Hypertension
    Interventions
    Irbesartan (Aprovel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-02
    Completion
    2006-11
    Enrolment
    1,630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan (Aprovel)
    PhasePhase 4
    Registry statusCompleted

  • Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers

    NCT00225667 · start 2005-12

    Registered record
    Registry ID
    NCT00225667
    Conditions
    Atrial Fibrillation; Hypertension
    Interventions
    Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2005-12
    Completion
    2007-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Hypertension
    InterventionIrbesartan
    PhasePhase 3
    Registry statusUnknown

  • Irbesartan in Hypertension

    NCT00265967 · start 2005-09

    Registered record
    Registry ID
    NCT00265967
    Conditions
    Hypertension
    Interventions
    Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-09
    Completion
    Not recorded
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan
    PhasePhase 4
    Registry statusCompleted

  • PHARES Study: Management of Resistant Hypertension

    NCT00224549 · start 2005-04

    Registered record
    Registry ID
    NCT00224549
    Conditions
    Hypertension
    Interventions
    irbesartan, amlodipine and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2009-08
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionirbesartan, amlodipine and hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

    NCT00219115 · start 2005-01

    Registered record
    Registry ID
    NCT00219115
    Conditions
    Hypertension
    Interventions
    aliskiren
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-01
    Completion
    2006-03
    Enrolment
    493

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionaliskiren
    PhasePhase 3
    Registry statusCompleted

  • Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

    NCT00095550 · start 2004-10

    Registered record
    Registry ID
    NCT00095550
    Conditions
    Hypertension
    Interventions
    Irbesartan/HCTZ; Irbesartan monotherapy; HCTZ monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-10
    Completion
    2005-06
    Enrolment
    496

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan/HCTZ; Irbesartan monotherapy; HCTZ monotherapy
    PhasePhase 3
    Registry statusCompleted

  • Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

    NCT00095290 · start 2004-09

    Registered record
    Registry ID
    NCT00095290
    Conditions
    Albuminuria
    Interventions
    Ramipril + Irbesartan; Ramipril + Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-09
    Completion
    2005-11
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlbuminuria
    InterventionRamipril + Irbesartan; Ramipril + Placebo
    PhasePhase 4
    Registry statusCompleted

  • Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria

    NCT00561964 · start 2004-01

    Registered record
    Registry ID
    NCT00561964
    Conditions
    Hypertension
    Interventions
    Irbesartan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2005-07
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan; placebo
    PhasePhase 3
    Registry statusCompleted

  • Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

    NCT00243178 · start 2003-07

    Registered record
    Registry ID
    NCT00243178
    Conditions
    Atrial Fibrillation; Vascular Risk
    Interventions
    clopidogrel (SR25990C)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-07
    Completion
    2005-09
    Enrolment
    6,706

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Vascular Risk
    Interventionclopidogrel (SR25990C)
    PhasePhase 3
    Registry statusTerminated

  • Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.

    NCT00154024 · start 2003-03

    Registered record
    Registry ID
    NCT00154024
    Conditions
    Healthy Subjects
    Interventions
    atorvastatin; irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-03
    Completion
    2006-10
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    Interventionatorvastatin; irbesartan
    PhaseNot applicable
    Registry statusCompleted

  • Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice

    NCT00564187 · start 2003-02

    Registered record
    Registry ID
    NCT00564187
    Conditions
    Hypertension
    Interventions
    Irbesartan; Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-02
    Completion
    2004-12
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan; Irbesartan
    PhasePhase 4
    Registry statusCompleted